Catalent
3Q Revenues: $627.9 million (+18%)
3Q Earnings: $19.0 million (-27%)
YTD Revenues: $1.8 billion (+18%)
YTD Earnings: $0.9 million (earnings were $48 million YTD17)
Comments: Revenue from the Softgel Technologies segment was $228.5 million in the quarter, up 9% primarily attributable to the February 2017 Accucaps acquisition. Revenue from the Drug Delivery Solutions segment was $313.6 million, an increase of 34%. This growth was primarily attributable to the Cook Pharmica acquisition which contributed 26 percentage points. Clinical Supply Services segment revenue was $104.4 million, up 7% due to higher volume related to storage and distribution services, partially offset by volume declines related to manufacturing and packaging services, as well as lower comparator sourcing volume. The nine months FY18 includes a tax charge of $51.6 million as a provisional estimate of the net accounting impact of the recently enacted U.S. tax law changes.